Abstract: Parkinson’s Disease (PD) is a progressive neurological disorder that primarily affects motor functions and can lead to mild cognitive impairment (MCI) and dementia in its advanced stages.
Strategic Implications: Analytical findings reported today underscore ABP-450’s potential to become the first full label therapeutic biosimilar to BOTOX® in the U.S., positioning AEON to address a >$3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback